Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 24560251)

1.

Recurrent ischemic stroke in a patient with the Trousseau syndrome treated with dabigatran.

Yoshida K, Kimura T, Aburakawa Y, Suzuki Y, Kuroda K, Yahara O.

J Stroke Cerebrovasc Dis. 2014 Jul;23(6):1724-6. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.019. Epub 2014 Feb 20.

PMID:
24560251
2.

Thrombolysis in ischemic stroke patients on treatment with Dabigatran.

Re G, Toni D.

Intern Emerg Med. 2013 Aug;8(5):451-2. doi: 10.1007/s11739-013-0907-0. Epub 2013 Feb 7. No abstract available.

PMID:
23389386
3.

Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.

Kate M, Szkotak A, Witt A, Shuaib A, Butcher K.

J Stroke Cerebrovasc Dis. 2014 Jul;23(6):1351-5. doi: 10.1016/j.jstrokecerebrovasdis.2013.11.013. Epub 2014 Jan 7.

PMID:
24406026
4.

Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.

Kono S, Deguchi K, Omote Y, Yunoki T, Yamashita T, Kurata T, Ikeda Y, Abe K.

J Neurosci Res. 2014 Jan;92(1):46-53. doi: 10.1002/jnr.23302. Epub 2013 Nov 4.

PMID:
24265137
5.

Acute ischemic stroke following cardioversion in a patient receiving dabigatran.

Faust AC, Smith MB, Kawalsky D.

Ann Pharmacother. 2013 Oct;47(10):1368-71. doi: 10.1177/1060028013500941.

PMID:
24259703
6.

Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.

Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Lane DA, Lip GY.

Am J Med. 2014 Dec;127(12):1172-8.e5. doi: 10.1016/j.amjmed.2014.07.023. Epub 2014 Sep 1.

PMID:
25193361
7.

[Waiting for the new oral anticoagulants: questions and answers about dabigatran].

Verdecchia P, Agnelli G.

G Ital Cardiol (Rome). 2013 Jan;14(1):35-45. doi: 10.1714/1207.13371. Review. Italian.

PMID:
23258203
8.

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators.

Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.

PMID:
22084332
9.

Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.

Chevalier J, Giroud M, de Pouvourville G.

Cerebrovasc Dis. 2013;35(4):320-6. doi: 10.1159/000347074. Epub 2013 Apr 23.

PMID:
23615428
10.

Warfarin versus dabigatran: comparing the old with the new.

Abraham ME, Marcy TR.

Consult Pharm. 2012 Feb;27(2):121-4. doi: 10.4140/TCP.n.2012.121. Review.

PMID:
22330953
11.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
12.

Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.

Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):567-74. doi: 10.1161/CIRCOUTCOMES.113.000192. Epub 2013 Aug 6. Erratum in: Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e59.

13.

Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.

Fieland D, Taylor M.

Ann Pharmacother. 2012 Jan;46(1):e3. doi: 10.1345/aph.1Q474. Epub 2011 Dec 27.

PMID:
22202498
14.

Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.

Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S.

J Am Coll Cardiol. 2013 Sep 3;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042. Epub 2013 Jun 13.

15.

Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.

Morales-Vidal S, Schneck MJ, Flaster M, Biller J.

Expert Rev Neurother. 2012 Feb;12(2):179-89; quiz 190. doi: 10.1586/ern.11.185. Review.

PMID:
22288673
16.

Dabigatran: will it change clinical practice?

Wartak SA, Bartholomew JR.

Cleve Clin J Med. 2011 Oct;78(10):657-64. doi: 10.3949/ccjm.78a.11021.

17.

Stroke thrombolysis in patients taking dabigatran.

Jayathissa S, Gommans J, Harper P.

Intern Med J. 2013 Jul;43(7):826-8. doi: 10.1111/imj.12182. Review.

PMID:
23841763
18.

Dabigatran, intracranial hemorrhage, and the neurosurgeon.

Awad AJ, Walcott BP, Stapleton CJ, Yanamadala V, Nahed BV, Coumans JV.

Neurosurg Focus. 2013 May;34(5):E7. doi: 10.3171/2013.2.FOCUS1323. Review.

PMID:
23634926
19.

Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.

Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ.

Circulation. 2012 Feb 7;125(5):669-76. doi: 10.1161/CIRCULATIONAHA.111.055970. Epub 2012 Jan 3.

20.

Using dabigatran in patients with stroke: a practical guide for clinicians.

Alberts MJ, Bernstein RA, Naccarelli GV, Garcia DA.

Stroke. 2012 Jan;43(1):271-9. doi: 10.1161/STROKEAHA.111.622498. Epub 2011 Dec 8. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk